A Study of Sinotecean on Tolerance and Pharmacokinetics

Inclusion Criteria: * late malignant tumor patients diagnosed with the pathological and/or cytological; * lack of the standard treatment or treatment failure; * 18-65years, ECOG:0-1,expected survival period \>3 months; * main organs function is normal; * signed and dated informed consent Exclusion Criteria: * participated in other clinical trials in four weeks; * currently under other effective treatment; * end of anti-tumor treatment within 4 weeks(end of Nitrosourea/Mitomycin within 6 weeks); * AE ≥ Grade 2(according to NCI-CTC 4.0),except hair loss; * with ischemic heart disease, heart failure, severe arrhythmia, cerebrovascular disease, asthma, severe infections, active peptic ulcer; * urine protein: ++, and urinary in 24 hours \> 1.0g; * uncontrolled primary or metastatic brain; * have immunodeficiency history; * according to the researcher's judgment,there are concomitant diseases which will seriously endanger the patients or obstruct the patients to complete the clinical trial;